NCT05386043Recruiting
Registering Genomics and Imaging of Tumors (ReGIT)
Source: ClinicalTrials.gov · Last updated 15 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 26 Apr 2022
- Start date
- 18 Jul 2023
- Primary completion date
- 17 Jul 2030
- Lead sponsor
- Indiana University
- Diseases
- Glioblastoma
- NCT number
- NCT05386043
What you commit to
- Study type: Observational
- Planned participants: 20
- From 18 Jul 2023 to the primary completion date, 17 Jul 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subject has insufficient tissue to acquire at least two biopsy samples during resection.
Other illness
- Subject has conditions that would preclude the completion of an MRI such as claustrophobia, pacemaker, metal objects in the body, and/or pregnancy.
- Subject has serious unstable medical or mental illness.
Lab values
- Subject is at high risk for NSF (eGFR\<60 or serum creatine \>1.3) and cannot follow the weight-based dosing protocol for Gadavist.\*\*\*
Other
- Subject has a medical contraindication to any element of the study procedures.
- Subject or their LAR has not read and signed the informed consent form, or does not understand its contents.
- Subject is pregnant.\*\*
Who the study is looking for
- Subject is between 18 and 89 years of age.
- Subject has radiologically-diagnosed or suspected WHO Grade II-IV glioma based on physician review or conformance with published WHO criteria as evaluated by the PI\*.
- Subject is treatment-naïve with the exception of previous biopsy for the above condition.
- Subject is planning to undergo surgical resection and biopsy of their brain tumor.
- Subject has sufficient tissue so that the study team is able to acquire at least 2 biopsy samples during resection.
- Subject is able to read and write in English.
- Subject is able to lay supine for up to 80 minutes.
- Subject is able to hold still during MRI procedures.
- Subject or their LAR has signed the consent form for participation in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Indiana University School of Medicine Coordinator of this site? Confirm its status | Indianapolis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.